These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26136587)

  • 1. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
    Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
    J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
    Pirazzi C; Valenti L; Motta BM; Pingitore P; Hedfalk K; Mancina RM; Burza MA; Indiveri C; Ferro Y; Montalcini T; Maglio C; Dongiovanni P; Fargion S; Rametta R; Pujia A; Andersson L; Ghosal S; Levin M; Wiklund O; Iacovino M; Borén J; Romeo S
    Hum Mol Genet; 2014 Aug; 23(15):4077-85. PubMed ID: 24670599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans.
    Kovarova M; Königsrainer I; Königsrainer A; Machicao F; Häring HU; Schleicher E; Peter A
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1568-74. PubMed ID: 26439088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
    Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
    J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life.
    Romeo S; Sentinelli F; Cambuli VM; Incani M; Congiu T; Matta V; Pilia S; Huang-Doran I; Cossu E; Loche S; Baroni MG
    J Hepatol; 2010 Aug; 53(2):335-8. PubMed ID: 20546964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.
    Palmer CN; Maglio C; Pirazzi C; Burza MA; Adiels M; Burch L; Donnelly LA; Colhoun H; Doney AS; Dillon JF; Pearson ER; McCarthy M; Hattersley AT; Frayling T; Morris AD; Peltonen M; Svensson PA; Jacobson P; Borén J; Sjöström L; Carlsson LM; Romeo S
    PLoS One; 2012; 7(6):e39362. PubMed ID: 22724004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
    Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
    World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
    BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
    Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
    Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
    Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
    Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
    Lin YC; Chang PF; Chang MH; Ni YH
    Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals.
    Nishioji K; Mochizuki N; Kobayashi M; Kamaguchi M; Sumida Y; Nishimura T; Yamaguchi K; Kadotani H; Itoh Y
    PLoS One; 2015; 10(10):e0140427. PubMed ID: 26485523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
    Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
    Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A; Ruhl CE
    Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.